389 related articles for article (PubMed ID: 30630446)
1. Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1.
Baloch T; López-Ozuna VM; Wang Q; Matanis E; Kessous R; Kogan L; Yasmeen A; Gotlieb WH
BMC Cancer; 2019 Jan; 19(1):44. PubMed ID: 30630446
[TBL] [Abstract][Full Text] [Related]
2. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
3. The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.
Wichmann C; Klotz DM; Zeiler HJ; Hilger RA; Grützmann K; Krüger A; Aust D; Wimberger P; Kuhlmann JD
Gynecol Oncol; 2020 Dec; 159(3):850-859. PubMed ID: 32980128
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells.
Ciccone MA; Adams CL; Bowen C; Thakur T; Ricker C; Culver JO; Maoz A; Melas M; Idos GE; Jeyasekharan AD; Matsuo K; Roman LD; Gruber SB; McDonnell KJ
Gynecol Oncol; 2020 Dec; 159(3):869-876. PubMed ID: 33032822
[TBL] [Abstract][Full Text] [Related]
5. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
6. Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification.
Gasimli K; Raab M; Tahmasbi Rad M; Kurunci-Csacsko E; Becker S; Strebhardt K; Sanhaji M
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142803
[TBL] [Abstract][Full Text] [Related]
7. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
8. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
Kondrashova O; Topp M; Nesic K; Lieschke E; Ho GY; Harrell MI; Zapparoli GV; Hadley A; Holian R; Boehm E; Heong V; Sanij E; Pearson RB; Krais JJ; Johnson N; McNally O; Ananda S; Alsop K; Hutt KJ; Kaufmann SH; Lin KK; Harding TC; Traficante N; ; deFazio A; McNeish IA; Bowtell DD; Swisher EM; Dobrovic A; Wakefield MJ; Scott CL
Nat Commun; 2018 Sep; 9(1):3970. PubMed ID: 30266954
[TBL] [Abstract][Full Text] [Related]
9. Targeting on poly(ADP-ribose) polymerase activity with DNA-damaging hybrid lactam-steroid alkylators in wild-type and BRCA1-mutated ovarian cancer cells.
Trafalis DT; Polonifi A; Dalezis P; Nikoleousakos N; Katsamakas S; Sarli V
Chem Biol Drug Des; 2017 Nov; 90(5):854-866. PubMed ID: 28432813
[TBL] [Abstract][Full Text] [Related]
10. Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
Moustafa D; Elwahed MRA; Elsaid HH; Parvin JD
PLoS One; 2021; 16(1):e0235025. PubMed ID: 33412559
[TBL] [Abstract][Full Text] [Related]
11. Integrated proteomics identifies PARP inhibitor-induced prosurvival signaling changes as potential vulnerabilities in ovarian cancer.
Deng O; Dash S; Nepomuceno TC; Fang B; Yun SY; Welsh EA; Lawrence HR; Marchion D; Koomen JM; Monteiro AN; Rix U
J Biol Chem; 2022 Nov; 298(11):102550. PubMed ID: 36183837
[TBL] [Abstract][Full Text] [Related]
12. Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma.
Watson ZL; Yamamoto TM; McMellen A; Kim H; Hughes CJ; Wheeler LJ; Post MD; Behbakht K; Bitler BG
Clin Epigenetics; 2019 Nov; 11(1):165. PubMed ID: 31775874
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
Hijaz M; Chhina J; Mert I; Taylor M; Dar S; Al-Wahab Z; Ali-Fehmi R; Buekers T; Munkarah AR; Rattan R
Gynecol Oncol; 2016 Aug; 142(2):323-31. PubMed ID: 27282964
[TBL] [Abstract][Full Text] [Related]
14. Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in
Kim H; George E; Ragland R; Rafail S; Zhang R; Krepler C; Morgan M; Herlyn M; Brown E; Simpkins F
Clin Cancer Res; 2017 Jun; 23(12):3097-3108. PubMed ID: 27993965
[No Abstract] [Full Text] [Related]
15. Proteomic Analysis Reveals Low-Dose PARP Inhibitor-Induced Differential Protein Expression in BRCA1-Mutated High-Grade Serous Ovarian Cancer Cells.
Perez JM; Twigg CAI; Guan W; Thomas SN
J Am Soc Mass Spectrom; 2022 Feb; 33(2):242-250. PubMed ID: 34958553
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 expression is epigenetically repressed in sporadic ovarian cancer cells by overexpression of C-terminal binding protein 2.
May T; Yang J; Shoni M; Liu S; He H; Gali R; Ng SK; Crum C; Berkowitz RS; Ng SW
Neoplasia; 2013 Jun; 15(6):600-8. PubMed ID: 23730208
[TBL] [Abstract][Full Text] [Related]
17. BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Stordal B; Timms K; Farrelly A; Gallagher D; Busschots S; Renaud M; Thery J; Williams D; Potter J; Tran T; Korpanty G; Cremona M; Carey M; Li J; Li Y; Aslan O; O'Leary JJ; Mills GB; Hennessy BT
Mol Oncol; 2013 Jun; 7(3):567-79. PubMed ID: 23415752
[TBL] [Abstract][Full Text] [Related]
18. The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.
Morra F; Merolla F; Damia G; Ricci F; Varricchio S; Ilardi G; Arenare L; Califano D; Napolitano V; Fruscio R; Melillo RM; Palazzo L; Celetti A
J Exp Clin Cancer Res; 2022 Aug; 41(1):245. PubMed ID: 35964058
[TBL] [Abstract][Full Text] [Related]
19. Synergistic Effect of Bazedoxifene and PARP Inhibitor in the Treatment of Ovarian Cancer Regardless of BRCA Mutation.
Zhang R; Wang T; Lin J
Anticancer Res; 2021 May; 41(5):2277-2286. PubMed ID: 33952453
[TBL] [Abstract][Full Text] [Related]
20. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
Wiegmans AP; Yap PY; Ward A; Lim YC; Khanna KK
Mol Cancer Ther; 2015 Oct; 14(10):2321-31. PubMed ID: 26294743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
